CAR T-Cell Therapy Earns Indication for Lymphoma in First Relapse

(MedPage Today) -- The FDA approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) as initial treatment for relapsed/refractory large B-cell lymphoma (LBCL).
The action moves CAR T-cell therapy to...